The scientific focus adapted
to express the optimum potential
of your molecule

Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Previous events


02/07/2017 Physiogenex to present its 3-week NASH screening mouse model and the Diet-Induced NASH hamster model at the APASL 2017 in Shanghai.

Physiogenex will present its 3-week NASH screening model and the Diet-Induced NASH (DIN) hamster model during the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), February 15-19, 2017 in Shanghai, China. These models will be presented by Dr. François Briand, Director of Research and Business Development at Physiogenex, during oral abstracts […]

Read more


09/08/2016 Physiogenex and CLEA Japan Inc. present a novel 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at the New York Academy of Sciences.

Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting Diabetic Nephropathy. The Spontaneously Diabetic Torii fatty (SDT fatty) rat, a model of obesity type 2 diabetes distributed by CLEA Japan Inc. since 2012, has been […]

Read more

02/15/2016 Physiogenex to present its 2 major nutritional NASH mouse models to evaluate drugs targeting Non Alcoholic Fatty Liver Diseases (NAFLD) and Fibrosis at APASL 2016 in Tokyo

Using unique nutritional approaches, Physiogenex has developed novel NASH mouse models, to be presented on February, 23rd 2016, during the poster session of the Asian Pacific Association for the Study of the Liver (APASL) meeting in Tokyo

-one mouse model enabling a very fast evaluation and screening of drugs targeting NASH, in only 3 weeks.

-another mouse model replicating the human metabolic syndrome associated NASH and liver fibrosis in 16-week diet induced obese insulin resistant mice.

Read more



05/16/2014 Meet Physiogenex at AFSTAL, 4-6 June, 2014 in Toulouse, France

We are pleased to announce that Dr Sulpice will present on Wednesday, 4th regarding "the choice of predictive animal models for an improved predictivity of future clinical trials".

During the conference, come and meet our technical and sales team in our booth n°122.  They will be very pleased to discuss with you about your projects and present our services, capabilities and new models.


Read more